<DOC>
	<DOCNO>NCT02452515</DOCNO>
	<brief_summary>The purpose trial analysis safety tolerability chymase inhibitor BAY1142524 comparison placebo use 2 week treatment period clinically stable patient left-ventricular dysfunction myocardial infarction . BAY1142524 placebo give top evidence-based standard care left-ventricular dysfunction myocardial infarction . Primary objective analysis safety tolerability evidence incidence severity adverse event . BAY1142524 administer parallel group design use four dos ( 5 , 10 , 25 mg twice daily , 50 mg daily ) . Each dose group consist 9 patient treat verum 3 patient treated placebo .</brief_summary>
	<brief_title>A Single-blind Pilot Study Investigate Safety Tolerability Chymase Inhibitor BAY1142524 Clinically Stable Patients With Left-ventricular Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<criteria>Clinically stable patient leftventricular dysfunction ( LVEF ≤ 45 % ) myocardial infarction , whereby MI occur 6 month randomization . New York Heart Association ( NYHA ) class III . Leftventricular ejection fraction ≤ 45 % , confirm imaging technique within last 3 month prior screen visit accept screening purpose . If data available , echocardiography perform screening inclusion . Treatment evidencebased therapy leftventricular dysfunction post MI least 4 week prior screen visit . This therapy include least Angiotensinconverting enzyme ( ACE ) inhibitor Angiotensin receptor blocker ( ARB ) . Betablockers , diuretic , mineralocorticoid receptor antagonist ( MRAs ) , antiplatelet therapy , statin , aspirin use indicated . Treatment stable dos ACE inhibitor ARBs use least half recommend target dose ( defined European Society Cardiology ( ESC ) guideline , see appendix 16.4 ) ≥ 4 week prior screen visit mandatory . No planned change post MI drug therapy active treatment phase study . Men confirm postmenopausal woman ( define amenorrheic longer 2 year appropriate clinical profile , e.g . age appropriate history vasomotor symptom ) woman without childbearing potential base surgical treatment bilateral tubal ligation , bilateral oophorectomy hysterectomy ( documented medical report verification ) . Men reproductive potential must agree use 2 reliable acceptable method contraception simultaneously sexually active act sperm donor . This applies time period signing informed consent form 12 week last administration study drug . Acceptable method contraception include , limited , ( ) condom ( male female ) without spermicidal agent ; ( ii ) diaphragm cervical cap spermicide ; ( iii ) intrauterine device ; ( iv ) hormonebased contraception . Age : 40 79 year ( inclusive ) screen visit . Race : Caucasian Nonischemic cause cardiomyopathy exclude ( include , limited : primary cardiomyopathy , constrictive , restrictive hypertrophic cardiomyopathy , acute myocarditis , cardiomyopathy secondary cardiotoxic chemotherapeutic agent ) . Hospitalization decompensated heart failure within last 3 month prior randomization . Coronary revascularization within 6 week prior randomization revascularization anticipate need study duration . Clinically relevant , cardiac ischemia stress test within 3 month screen . Patients carry implantable cardioverter defibrillator , cardiac resynchronisation therapy device leave ventricular assist device significant clinical event require treatment change background medical therapy ventricular tachycardia , ventricular fibrillation last 6 month randomization carry device Primary uncorrected valvular disease foreseen requirement valve repair within next 6 month . Any stroke , TIA , acute coronary syndrome within 6 month prior randomization . Clinically relevant hepatic dysfunction screen visit indicate least one following : hepatic insufficiency ( ChildPugh B C ) document medical history total bilirubin &gt; 2 time upper limit normal ( ULN ) alanine amino transferase ( ALT ) &gt; 3 time ULN glutamate dehydrogenase ( GLDH ) &gt; 3 time ULN gamma glutamyl transpeptidase ( GGT ) &gt; 5 time ULN . Systolic blood pressure 100 160 mm Hg screen visit base average 3 reading take arm high recording .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>